Key result
Decellularized pulmonary homografts demonstrated significantly higher freedom from explantation (95.5% vs 81.7%) and degeneration (65.4% vs 39.6%) at 10 years compared to bovine jugular vein conduits.
Why the study?
Decellularized pulmonary homografts have emerged as an alternative to bovine jugular vein conduits for pulmonary valve replacement in congenital heart disease, but comparative data were needed.
Does decellularized pulmonary homograft improve freedom from explantation and endocarditis compared to bovine jugular vein conduits in patients with congenital heart disease requiring pulmonary valve replacement?
Comparison
Decellularized pulmonary homografts vs bovine jugular vein conduits
Design
Matched comparison cohort study
Follow-up
10 years
Authors
Loading...
Should not yet change PVR conduit choice; leaves open whether DPH superiority persists after size matching in prospective studies.
Cohort (n=638)
Yes
Does decellularized pulmonary homograft improve freedom from explantation and endocarditis compared to bovine jugular vein conduits in patients with congenital heart disease requiring pulmonary valve replacement?
Absolute Event Rate: 95.5% vs 81.7%
p-value: p=0.001
Decellularized pulmonary homografts demonstrate superior 10-year freedom from explantation, degeneration, and endocarditis compared to bovine jugular vein conduits for pulmonary valve replacement in congenital heart disease.
Bobylev et al. (2023) conducted a cohort in Congenital heart disease requiring pulmonary valve replacement (n=638). Decellularized pulmonary homografts vs. Bovine jugular vein conduits was evaluated on Freedom from explantation at 10 years (p=0.001). Decellularized pulmonary homografts demonstrated significantly higher freedom from explantation (95.5% vs 81.7%) and degeneration (65.4% vs 39.6%) at 10 years compared to bovine jugular vein conduits.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: